BioNTech ADRs rise on Phase 3 lung cancer data
BioNTech ADRs were up 3.7% to $110.34 as of midday Monday after the company said gotistobart nearly doubled median survival in a Phase 3 lung cancer trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.